Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Relapse of Covid-19-Associated Mucormycosis in Patients Receiving Posaconazole As Maintenance Treatment Publisher Pubmed



Salehi M1 ; Khodavaisy S2 ; Sarvestani HK2 ; Sobati A3 ; Pakdel F4 ; Fard ES1 ; Darvishi M5 ; Shavandi M6 ; Mussini C7 ; Rafat Z8 ; Ahmadikia K2 ; Tabari A9
Authors
Show Affiliations
Authors Affiliations
  1. 1. Research Center for Antibiotic Stewardship and Antimicrobial Resistance, Department of Infectious Diseases and Tropical Medicine, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran
  2. 2. Department of Medical Parasitology and Mycology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran
  3. 3. Department of Nursing and Midwifery, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran
  4. 4. Department of Oculo-Facial Plastic Surgery, Department of Ophthalmology, Farabi Hospital, Tehran University of Medical Sciences, Tehran, Iran
  5. 5. Shefa Neuroscience Research Center, Khatam Alanbia Hospital, Tehran, Iran
  6. 6. Rajaie Cardiovascular Medical and Research Institute, Tehran, Iran
  7. 7. Department of Infectious Diseases and Tropical Medicine, University of Modena and Reggio Emilia, Modena, Italy
  8. 8. Department of Medical Microbiology, School of Medicine, Guilan University of Medical Sciences, Rasht, Iran
  9. 9. Otorhinolaryngology Research Center, Imam Khomeini Hospital complex, Tehran University of Medical Sciences, Tehran, Iran

Source: Journal of Infection in Developing Countries Published:2024


Abstract

Introduction: Coronavirus disease 2019 (COVID-19) has been associated with secondary fungal infections such as mucormycosis. We investigated the relapse rate of mucormycosis and its risk factors. Methodology: A prospective study was conducted on COVID-19-associated mucormycosis (CAM) patients discharged from Imam Khomeini Hospital Complex, Tehran, Iran, from July 2021 to February 2022. Patients who received posaconazole as a step-down therapy were included and examined monthly for six months. A relapsing mucormycosis case was defined as a patient with new clinical or radiological symptoms, confirmed by observing aseptate hyphae in the histopathological examination or tissue culture. The characteristics of patients with and without relapse were analyzed and compared. Results: Seventy-seven patients completed the six-month follow-up after discharge. Most patients were male (n = 46, 59.8%), with a mean age of 53.1 years (median 19-84). The most common underlying diseases were diabetes (52/77, 67.5%), hypertension (33/77, 42.8%), and cancer/chemotherapy (25/77, 32.4%). Seven patients (7/77, 9%) were reported as relapsing cases. There was no difference in demographic features and underlying diseases between the groups. A significant difference was seen in the mean duration of posaconazole consumption between patients with and without relapse (24 ± 4.4 days vs. 49.4 ± 4.3 days, respectively, p = 0.015). The primary orbital involvement was also significantly associated with relapse (p = 0.04). Conclusions: Our findings showed a significant relapse of CAM (9%). A longer duration of posaconazole consumption and completion of treatment for initial orbital involvement in CAM patients are recommended for better patient management and prevention of relapse. © 2024 Salehi et al.
Related Docs
View other Related Docs
1. Practice Guideline on Prevention, Diagnosis, and Treatment of Rhino-Orbito-Cerebral Mucormycosis in the Covid-19 Area: A Consensus of Iranian Experts, Archives of Clinical Infectious Diseases (2022)
2. Covid‑19‑Associated Mucormycosis: A Review of an Emergent Epidemic Fungal Infection in the Era of Covid‑19 Pandemic, Journal of Research in Medical Sciences (2022)
3. Covid-19 Associated Rhino-Orbital-Cerebral Mucormycosis: Clinical Features, Antifungal Susceptibility, Management and Outcome in a Tertiary Hospital in Iran, Mycopathologia (2023)
4. Diabetes Mellitus and Other Underlying Conditions in Patients With Coronavirus Disease 2019 Associated Rhino-Orbito-Cerebral Mucormycosis: A Systematic Review and Meta-Analysis, Journal of Laryngology and Otology (2022)
5. Covid-19-Associated Fungal Infections in Iran: A Systematic Review, PLoS ONE (2022)
6. Covid-19 Associated Rhino-Orbito-Cerebral Mucormycosis, Risk Factors and Outcome Predictors; a Multicentric Study, International Ophthalmology (2023)
7. Risk Factors of Covid-19 Associated Mucormycosis (Cam) in Iranian Patients: A Single-Center Retrospective Study, Mycopathologia (2022)
8. Iranian Patients With Diabetes and Covid-19-Associated Mucormycosis: Characteristics, Manifestations, and Mortality Risk Factors, International Journal of Diabetes in Developing Countries (2024)
Experts (# of related papers)
View all Related Experts
Mohammadreza Salehi (11)
Sadegh Khodavaisy (8)
Other Related Docs
9. Proven Cutaneous Mucormycosis in a Covid-19 Patient: A Case Report and Literature Review, Iranian Journal of Pathology (2024)
10. Mixed Aspergillosis and Mucormycosis Infections in Patients With Covid-19: Case Series and Literature Review, Mycopathologia (2024)
11. Subglottic Mucormycosis in a Covid-19 Patient: A Rare Case Report, Oxford Medical Case Reports (2022)
12. Case Report: Covid-19-Associated Rhinosinusitis Mucormycosis Caused by Rhizopus Arrhizus: A Rare But Potentially Fatal Infection Occurring After Treatment With Corticosteroids, American Journal of Tropical Medicine and Hygiene (2021)
13. Multiple Maxillary Periodontal Abscesses As a Manifestation of Post-Coronavirus Disease 2019 Mucormycosis: A Case Report, Journal of Medical Case Reports (2023)
14. Covid-19 Associated Mucormycosis Surge: A Review on Multi-Pathway Mechanisms, Parasite Immunology (2024)
15. Molecular Assays Versus Mycological Methods for Diagnosis of Rhino Orbital Mucormycosis: Analysis of 120 Clinical Specimens From Covid-19 Patients, Mycopathologia (2025)
16. Challenges and Pitfalls in the Management of Rhino-Orbital Mucormycosis in Ophthalmology: A Highlighted Problem in the Covid-19 Era, Journal of Ophthalmic and Vision Research (2022)
17. Pneumocystis Pneumonia in Covid-19 Patients: A Comprehensive Review, Heliyon (2023)
18. Covid-19 Associated Mucormycosis (Cam) in Kashan, Iran: Clinical Presentations, Risk Factors, Management, and Outcomes, Infectious Diseases (2024)
19. Mucormycosis in Patients With Covid-19: A Cross-Sectional Descriptive Multicentre Study From Iran, Mycoses (2021)
20. Epidemiology, Clinical Features, Diagnosis and Treatment of Cerebral Mucormycosis in Diabetic Patients: A Systematic Review of Case Reports and Case Series, Mycoses (2020)
21. Comparing Efficacy and Safety of Different Doses of Dexamethasone in the Treatment of Covid-19: A Three-Arm Randomized Clinical Trial, Pharmacological Reports (2022)
22. Tocilizumab Failed to Reduce Mortality in Severe Covid-19 Patients: Results From a Randomized Controlled Clinical Trial, Iranian Journal of Allergy# Asthma and Immunology (2024)
23. Covid-19-Associated Mucormycosis in Diabetic Patients: The Tip of an Iceberg, Iranian Journal of Public Health (2022)
24. Anticoagulation in the Management of Septic Cavernous Sinus Thrombosis Secondary to Rhino-Orbito-Cerebral Mucormycosis: A Retrospective Real-World Experience, Current Journal of Neurology (2024)
25. Percentage of Th1 and Th17 Cells and Serum Level of Il-17 and Ifn-Γcytokines in Covid-19-Associated Mucormycosis, Medical Mycology (2023)
26. Comparison of Corticosteroids Types, Dexamethasone, and Methylprednisolone in Patients Hospitalized With Covid-19: A Systematic Review and Network Meta-Analysis, Global Epidemiology (2023)
27. Reply: Is High-Dose Glucocorticoid Beneficial in Covid-19?, European Respiratory Journal (2021)
28. A Case of Covid-19-Associated Rhino-Orbito-Cerebral Mucormycosis Caused by Apophysomyces Variabilis With a Review of the Literature, Frontiers in Cellular and Infection Microbiology (2022)
29. A Case of Covid-19-Associated Mucormycosis Due to Lichtheimia Ramosa, Journal of Clinical Laboratory Analysis (2023)
30. Molecular Identification of Causative Agents in 25 Cases With Mucormycosis in Iran, Archives of Clinical Infectious Diseases (2019)
31. Mucormycosis Infection in Patients With Covid-19: A Systematic Review, Health Science Reports (2022)
32. Black Fungus and Beyond: Covid-19 Associated Infections, Clinical Imaging (2022)
33. Features and Evaluation of Mucormycosis in Covid-19 Patients From Two Referral Hospitals in Iran, Journal of Medical Mycology (2024)
34. Distinguishing Characteristics of Covid-19-Associated Mucormycosis; a Case Series, Archives of Academic Emergency Medicine (2022)
35. Inherited Ifnar1 Deficiency in a Child With Both Critical Covid-19 Pneumonia and Multisystem Inflammatory Syndrome, Journal of Clinical Immunology (2022)
36. In Vitro Activity of Amphotericin B in Combination With Statins Against Clinical and Environmental Rhizopus Oryzae Strains, Iranian Journal of Public Health (2019)